ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Antibe Therapeutics Inc (QX)

Antibe Therapeutics Inc (QX) (ATBPF)

0.31825
0.00
( 0.00% )
Updated: 09:33:50

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.31825
Bid
0.3092
Ask
0.3264
Volume
-
0.00 Day's Range 0.00
0.24 52 Week Range 0.8855
Market Cap
Previous Close
0.31825
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
21,274
Shares Outstanding
52,637,091
Dividend Yield
-
PE Ratio
-1.16
Earnings Per Share (EPS)
-0.37
Revenue
6.99M
Net Profit
-19.48M

About Antibe Therapeutics Inc (QX)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Toronto, Ontario, Can
Founded
1970
Antibe Therapeutics Inc (QX) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker ATBPF. The last closing price for Antibe Therapeutics (QX) was $0.32. Over the last year, Antibe Therapeutics (QX) shares have traded in a share price range of $ 0.24 to $ 0.8855.

Antibe Therapeutics (QX) currently has 52,637,091 shares outstanding. The market capitalization of Antibe Therapeutics (QX) is $22.63 million. Antibe Therapeutics (QX) has a price to earnings ratio (PE ratio) of -1.16.

ATBPF Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.012554.105332024860.30570.33420.3057214590.31296365CS
4-0.39225-55.20760028150.71050.73310.24357600.36771076CS
12-0.4106-56.33532276870.728850.84250.24212740.52434361CS
26-0.04875-13.28337874660.3670.88550.24233060.5485871CS
52-0.12115-27.57168866640.43940.88550.24172960.50740184CS
156-4.30175-93.11147186154.6250.24197630.93638023CS
2600.1041548.64549276040.21415.880.2079893540.55111757CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.39
(0.00%)
4.5k
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.20
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.37
(0.00%)
6.19k
AACIArmada Acquisition Corporation I
$ 11.17
(0.00%)
5
AACGATA Creativity Global
$ 1.115
(0.00%)
115
AAGRAfrican Agriculture Holdings Inc
$ 0.39
(0.00%)
4.5k
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.20
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.37
(0.00%)
6.19k
AACIArmada Acquisition Corporation I
$ 11.17
(0.00%)
5
AACGATA Creativity Global
$ 1.115
(0.00%)
115
AKANAkanda Corporation
$ 0.1649
(0.00%)
25.21M
KTRAKintara Therapeutics Inc
$ 0.0895
(0.00%)
19.06M
AKBAAkebia Therapeutics Inc
$ 2.24
(0.00%)
14.58M
CISSC3is Inc
$ 0.0382
(0.00%)
13.97M
XLOXilio Therapeutics Inc
$ 1.21
(0.00%)
10.88M

ATBPF Discussion

View Posts
kahlua kahlua 7 months ago
Well the tablet re-formulation ended up being very costly from both a time and money perspective, so this pivot/re-formulation really better pay off with stellar p2 results. Hopefully we get the readout data prior to the end of Q2 2024. I still see this as a strong risk/reward setup, it’s just been the opportunity cost of having tied up the funds. Interest in the share price should pick up heading into Q1.
πŸ‘οΈ0
kahlua kahlua 1 year ago
This board is a ghost town.

My take on thecurrent situation with Antibe:

With a current $25M CAD m/c I think the risk/reward setup here is about 20% risk for 300%+ reward leading up to the phase 2 acute otena readout by late 2023. Worthy of a on of due diligence since there’s been a lot of costlyhiccups with this company but the shares are currently trading as though none of the underlying fundamentals matter at all.

The company has more than enough cash to fund the ph2 trial. They have pivoted from chronic to the acute pain market which, while smaller annual peak sales, offers a far more de-risked pathway to positive ph2 readout results and inevitable commercialization/buyout post ph3. The IP reformulation also demonstrably helps de-risk the results with a more rapid onset and significantly reduced dosing regime. This could enable them, once funds allow, to go back to chronic otena for a ph3. But the sweet spot is here and now for those with funds and about one year of patience.

What I’ve learned with biotechs is know your company very well but as important, know the cycle of when time and money are on your side or when they’re against you. All in my opinion.
πŸ‘οΈ0
treedoc treedoc 3 years ago

https://m.canadianinsider.com/node/7?ticker=ATE&fbclid=IwAR3q4E-W8ZRcSlyhCwwamdTOLXDHInLgVBGQMvuMDbrVj6Vy21eyzl-sN3M
πŸ‘οΈ0
treedoc treedoc 3 years ago

https://www.biospace.com/article/releases/antibe-therapeutics-provides-clinical-update-for-otenaproxesul/
πŸ‘οΈ0
treedoc treedoc 3 years ago
Received proxy material
πŸ‘οΈ0
treedoc treedoc 3 years ago
https://www.lelezard.com/en/news-19876628.html
πŸ‘οΈ0
RoadShowPartner RoadShowPartner 3 years ago
**Attention Accredited Investor and Shareholders**
Please feel free to tune in to hear directly from management in an exclusive Zoom presentation for accredited investors and shareholders. Company executives will be giving an overview of the story while discussing upcoming catalysts and answering live questions. Register using the link below:

https://www.eventbrite.com/e/antibe-therapeutics-inc-webinar-6222021-registration-159355880729?ref=enivtefor001&invite=MjA1MDk0NjcvZ3RvZGRtYXJrZXlAZ21haWwuY29tLzA%3D%0A&utm_source=eb_email&utm_medium=email&utm_campaign=inviteformalv2&utm_term=eventpage
πŸ‘οΈ0
treedoc treedoc 3 years ago
FDA clearance a bit dated but opens up US for stage 3 trials. Pretty sweet imo.

Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain http://ca.finance.yahoo.com/news/antibe-therapeutics-receives-fda-clearance-110000132.html?soc_src=community&soc_trk=ma
πŸ‘οΈ0
treedoc treedoc 3 years ago
Flying low under the USA radar.

https://antibethera.com/
πŸ‘οΈ0
treedoc treedoc 3 years ago
I’m pretty sure not many have looked into the potential this one has.
Long and IMO of coarse.
πŸ‘οΈ0
Mindoro99 Mindoro99 3 years ago
Yeah, baby!
πŸ‘οΈ0
treedoc treedoc 3 years ago
$5 US. That’s pretty.
πŸ‘οΈ0
Amatuer17 Amatuer17 3 years ago
After a long time - company found a partner and some funding.
Hopefully now they can move forward and give good results.
The product is good and has big potential in US
πŸ‘οΈ0
Mindoro99 Mindoro99 3 years ago
Excellent news, kudos to Dan and his team on this. More partnerships to come. Load up at these levels, still way undervalued!
πŸ‘οΈ0
treedoc treedoc 3 years ago

https://finance.yahoo.com/news/antibe-therapeutics-announces-strategic-licensing-120000925.html
πŸ‘οΈ0
dubt dubt 3 years ago
Ring the bell at tsx. Amazing what some exposure can do
πŸ‘οΈ0
Renee Renee 3 years ago
ATBPF one for 10 reverse split. **PPS closed at .30

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
πŸ‘οΈ0
dubt dubt 3 years ago
Not great seemingly
πŸ‘οΈ0
dubt dubt 3 years ago
See how the Canadian up listing will treat the stock. Positive so far with announcement
πŸ‘οΈ0
DirtyPenny DirtyPenny 3 years ago
386,782,798 added another million plus to the o/s
πŸ‘οΈ0
Ecomike Ecomike 3 years ago
Interesting biotech that has almost no volume, compared to similar ones, maybe the volume is north of the border?

The Drug and potential is very interesting. On my radar now.

Will major news and whole lot volume to break and run big time.

And time line on the Phase III trial?
πŸ‘οΈ0
DirtyPenny DirtyPenny 4 years ago
more added, outstanding now 385,516,301
they added +100 million shares since last year.
πŸ‘οΈ0
janeyH janeyH 4 years ago
continues to be shit on
πŸ‘οΈ0
DirtyPenny DirtyPenny 4 years ago
added 19 million shares since 3/30, is this another dilution pos
πŸ‘οΈ0
janeyH janeyH 4 years ago
continues to be shit on
πŸ‘οΈ0
treedoc treedoc 4 years ago
Halt!
πŸ‘οΈ0
Amatuer17 Amatuer17 4 years ago
Heard the cc and Q&A

They were all very positive - all plan for next steps.

The phase 2/3 is good but with 12 week trial with 300+ patients and split into 2 phases - I think it is a long road and funding may be an issue.
πŸ‘οΈ0
dubt dubt 4 years ago
Yeah, not sure if people were just expecting a blow up instantly, but with the current MC to the potential I think we should see some real growth and pops at in partnership and other milestone. This is a multi dollar stock.
πŸ‘οΈ0
janeyH janeyH 4 years ago
wow, but continued doo-doo-ing in the stock - big volume
πŸ‘οΈ0
dubt dubt 4 years ago
Everything positive from the CC. lots of details, i believe they will put the transcript up on the website. Timelines haven't changed. everything moving forward as planned on better than expected results.
πŸ‘οΈ0
janeyH janeyH 4 years ago
great - pls let us know what you think
πŸ‘οΈ0
dubt dubt 4 years ago
I’m on it
πŸ‘οΈ0
janeyH janeyH 4 years ago
can’t make it - can anyone else?
πŸ‘οΈ0
dubt dubt 4 years ago
Conference call June 4
πŸ‘οΈ0
janeyH janeyH 4 years ago
Especially given the volume here two days of very heavy downward volume
πŸ‘οΈ0
Amatuer17 Amatuer17 4 years ago
Agree - I cannot see any update from company or someone on why such a bad reaction.
I thought the results were good
πŸ‘οΈ0
janeyH janeyH 4 years ago
i am surprised by the degree of the sell off here
πŸ‘οΈ0
waltd waltd 4 years ago
I sold 30k at .45 and got out, should have sold friday, better not complain as douled money and dont like the action, good news and fall ? im moving on!
πŸ‘οΈ0
DirtyPenny DirtyPenny 4 years ago
happens often, investors buy the rumor/speculation, then sell the news.
good luck
πŸ‘οΈ0
Mogles Mogles 4 years ago
The market is failing to price these results into the share price. Wasn’t expecting shares to go down on positive news. What was the market expecting here, FDA approval. Any guesses as to stock performance? This company is very undervalued for its stage of development and product pipeline.
πŸ‘οΈ0
treedoc treedoc 4 years ago
Very good news Amatuer17.
πŸ‘οΈ0
Amatuer17 Amatuer17 4 years ago
Results out - they look very good as expected.

All 3 doses showed very good results and top 2 doses showed statistical significance . New registrational pivotal P2/3 trial being planned.


https://finance.yahoo.com/news/antibe-therapeutics-announces-positive-top-103000987.html
πŸ‘οΈ0
NotTheFace1337 NotTheFace1337 4 years ago
Woot! Ty!
πŸ‘οΈ0
djmurdock djmurdock 4 years ago
https://www.bnnbloomberg.ca/video/robert-mcwhirter-discusses-antibe-therapeutics~1968070
πŸ‘οΈ0
NotTheFace1337 NotTheFace1337 4 years ago
So what I miss lol?
πŸ‘οΈ0
djmurdock djmurdock 4 years ago
https://www.facebook.com/watch/?v=365342554408162
πŸ‘οΈ0
djmurdock djmurdock 4 years ago
I expected a delay, just not that much. I have a feeling it will be 2-3 weeks and they wanted to be safe give themselves a buffer zone.
πŸ‘οΈ0
Mogles Mogles 4 years ago
Great hire in Dr Stauffer as Chief Medical Officer. Shows management’s confidence in P2b.
πŸ‘οΈ0
Mindoro99 Mindoro99 4 years ago
Another 6 weeks, apparently.....
πŸ‘οΈ0
Amatuer17 Amatuer17 4 years ago
6 more weeks - well at least they have all the data and no impact on trial parameters.


https://finance.yahoo.com/news/antibe-therapeutics-updates-timing-top-103000962.html
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock